Acetaminophen Toxicity Calculator

At therapeutic doses roughly 90 percent of an acetaminophen dose is conjugated by glucuronidation and sulfation into inert metabolites excreted in urine. A minor fraction passes through cytochrome P450, chiefly CYP2E1, producing N-acetyl-p-benzoquinone imine (NAPQI), a reactive electrophile immediately quenched by hepatic glutathione. In overdose the conjugation pathways saturate, NAPQI output rises, and once glutathione falls below roughly 30 percent of baseline the excess binds covalently to cysteine residues on mitochondrial proteins in centrilobular hepatocytes, producing the characteristic zone 3 necrosis. The commonly used risk threshold for a single acute ingestion is 150 mg/kg or 7.5 g, whichever is smaller, with 200 and 300 mg/kg marking higher risk. Chronic alcohol use, fasting and malnutrition, and CYP2E1 inducers shift the threshold downward by depleting glutathione and increasing NAPQI production. The Rumack-Matthew treatment line encodes this as a concentration-time relationship: 150 micrograms/mL at 4 hours post-ingestion, decaying with an assumed 4-hour half-life to about 4.7 micrograms/mL at 24 hours, with a level above the line indicating enough exposure to warrant acetylcysteine. The nomogram is valid only for a single acute ingestion with a reliably known time, sampled between 4 and 24 hours; it does not apply to staggered or repeated supratherapeutic dosing, unknown timing, or modified-release preparations. Acetylcysteine restores glutathione precursor supply and is near fully protective within 8 hours, but still reduces mortality given late in established hepatic failure. Prognostic escalation uses the Kings College criteria: arterial pH below 7.30 after resuscitation, or the combination of INR above 6.5, creatinine above 3.4 mg/dL, and grade III or IV encephalopathy.

Acetaminophen was first synthesised by Harmon Northrop Morse in 1878 but stayed obscure until Bernard Brodie and Julius Axelrod showed in 1948 that it was the active metabolite responsible for the analgesic effect of acetanilide, while the methaemoglobinaemia that had discredited acetanilide came from a different metabolite. Marketed widely from the 1950s as a safer alternative to aspirin and phenacetin, it acquired a reputation for benignity that its overdose profile did not support. Fatal hepatic necrosis after deliberate overdose was documented in Britain in the 1960s, with Davidson and Eastham reporting cases in the British Medical Journal in 1966, and the NAPQI and glutathione mechanism was worked out at the National Institutes of Health in the early 1970s. Barry Rumack and Henry Matthew published the concentration-versus-time nomogram in Pediatrics in 1975, giving clinicians the first objective way to decide who needed treatment rather than relying on reported dose alone. In practice most poison centres shifted the decision line down from the original 200 micrograms/mL to 150 to widen the safety margin. Laurie Prescott and colleagues in Edinburgh established intravenous acetylcysteine in the late 1970s, and the twenty-one hour regimen delivering 150, 50 and 100 mg/kg in sequence still carries his name; the seventy-two hour oral regimen was described by Smilkstein and coworkers in the 1980s. The Kings College criteria for transplantation were published by John O'Grady and colleagues in 1989.